Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | BDKRB2 | P30411 | 3/20 | 0.33 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18195185 | 1.00 | LMNA (0.37) | LMNACA2BDKRB2CSNK1EPRSS1 | |
| SCHEMBL15785191 | 1.00 | LMNA (0.37) | LMNACA2BDKRB2CSNK1EPRSS1 | |
| SCHEMBL17754978 | 1.00 | LMNA (0.37) | LMNACA2BDKRB2CSNK1EPRSS1 | |
| SCHEMBL31189960 | 0.98 | LMNA (0.36) | LMNACA2BDKRB2CSNK1EPRSS1 | |
| SCHEMBL31189959 | 0.98 | LMNA (0.36) | LMNACA2BDKRB2CSNK1EPRSS1 | |
| SCHEMBL19799279 | 0.94 | LMNA (0.35) | LMNACA2BDKRB2CSNK1EPRSS1 | |
| SCHEMBL29703309 | 0.85 | LMNA (0.38) | LMNACA2BDKRB2CSNK1EPRSS1 | |
| SCHEMBL18750444 | 0.82 | LMNA (0.36) | LMNACA2BDKRB2CSNK1EPRSS1 | |
| SCHEMBL32679416 | 0.82 | LMNA (0.36) | LMNACA2BDKRB2CSNK1EPRSS1 | |
| SCHEMBL28961636 | 0.82 | LMNA (0.36) | LMNACA2BDKRB2CSNK1EPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180013069-A1 | CONJUGATED POLYMERS BASED ON TERTHIOPHENE AND THEIR APPLICATIONS | RAYNERGY TEK INC. (TW) | 2018-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180013069-A1 | CONJUGATED POLYMERS BASED ON TERTHIOPHENE AND THEIR APPLICATIONS | TERT, TTI2, TTI1 | LMNA 4523/4885CA2 4849/4885BDKRB2 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.